Severe Uncontrolled Asthma and Monoclonal Antibodies

To participate in this activity, please start here:

Welcome to this webcast on the role and use of targeted therapy with monoclonal antibodies for the treatment of patients with severe uncontrolled asthma. This activity takes a deep dive into asthma phenotypes, including the role of biomarkers, and how this information is used to select biologic therapy. Clinical criteria for assessing treatment response are also discussed.

Want to learn more?
Visit Part 2 to learn more about phenotypes, biomarkers, and how to select monoclonal antibody agents.

Course Credit:

1.00 AANP Contact Hour
1.00 AMA PRA Category 1 CreditTM

Dates:

Opens: 2020-07-31
Closes: 2021-07-30

Target Audience:

This activity is intended for allergists, pulmonologists, and other clinicians interested in the management of patients with severe uncontrolled asthma.

This educational activity is supported by an educational grant from GlaxoSmithKline.
  • Jonathan Corren, MD

    Clinical Associate Professor of Medicine and Pediatrics
    Division of Clinical Immunology Allergy, Co-Director
    UCLA Nasal and Sinus Disease Center
    Medical Director, Allergy Research Foundation
    Los Angeles, California

Learning Objectives

  • Appraise the latest developments, including monoclonal antibody therapies, in the treatment of patients with severe uncontrolled asthma
  • Differentiate between currently available monoclonal antibody therapy for severe uncontrolled asthma
  • Assess and integrate factors determining the choice of monoclonal antibody therapy for patients with severe uncontrolled asthma

Faculty Disclosures

Jonathan Corren, MD

Research Support

  • AstraZeneca – clinical area: Asthma
  • Genentech/Roche – clinical area: Asthma, nasal polyps
  • Novartis – clinical area: Chronic urticaria
  • Regeneron – clinical area: Asthma, eosinophilic esophagitis
  • Sanofi – clinical area: Asthma, eosinophilic esophagitis

Consultant

  • AstraZeneca – clinical area: Asthma
  • Genentech/Roche – clinical area: Asthma, nasal polyps
  • Novartis – clinical area: Chronic urticaria
  • Regeneron – clinical area: Asthma, eosinophilic esophagitis
  • Sanofi – clinical area: Asthma, eosinophilic esophagitis

Speakers Bureau

  • AstraZeneca – clinical area: Asthma
  • Genentech/Roche – clinical area: Asthma, nasal polyps
  • Novartis – clinical area: Chronic urticaria
  • Regeneron – clinical area: Asthma, eosinophilic esophagitis
  • Sanofi – clinical area: Asthma, eosinophilic esophagitis

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.
This program is designated for up to 1.00 contact hour. Program ID# 5811-EM1.

Additional Content Planners

Juan Cardet, MD (Peer Reviewer)
No significant relationships to disclose.

Heather M. Jimenez, FNP-C (Lead Nurse Planner)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.